Relative potency of amiloride and spironolactone in healthy man

[1]  R. Perkins,et al.  Spironolactone dose-response relationships in healthy subjects. , 1982, British journal of clinical pharmacology.

[2]  R. Perkins,et al.  Quantitative comparison of aldosterone antagonists in normal human subjects: prediction of therapeutic potency. , 1981, British journal of clinical pharmacology.

[3]  L. Ramsay,et al.  Amiloride, spironolactone, and potassium chloride in thiazide‐treated hypertensive patents , 1980, Clinical pharmacology and therapeutics.

[4]  J. Ménard,et al.  Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker, acebutolol, and diuretics in essential hypertension. , 1978, The American journal of medicine.

[5]  J. Shelton,et al.  Spironolactone and canrenoate‐K: Relative potency at steady state , 1977, Clinical pharmacology and therapeutics.

[6]  J. Shelton,et al.  Spironolactone and potassium canrenoate in normal man , 1976, Clinical pharmacology and therapeutics.

[7]  L. Ramsay,et al.  Canrenone--the principal active metabolite of spironolactone? , 1976, British journal of clinical pharmacology.

[8]  L. Ramsay,et al.  The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects. , 1976, British journal of clinical pharmacology.

[9]  L. Ramsay,et al.  Relative potency of prorenoate and spironolactone in normal man , 1975, Clinical pharmacology and therapeutics.

[10]  P. Hessian,et al.  Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses. , 1975, British journal of clinical pharmacology.

[11]  C. Dollery,et al.  Comparison of the potassium- retaining effects of amiloride and spironolactone in hypertensive patients with thiazide-induced hypokalaemia. , 1973, Lancet.

[12]  P. Kincaid‐smith,et al.  A new look at the treatment of severe hypertension. , 1973, Clinical science and molecular medicine. Supplement.

[13]  R. Burden,et al.  The diagnostic and therapeutic value of spironolactone in patients with systemic hypertension. , 1972, Nephron.

[14]  A. Struyvenberg,et al.  Significance of hypokalaemia due to diuretics. , 1973, The Netherlands journal of medicine.

[15]  G. Wilson,et al.  Clinical evaluation of amiloride, a potassium‐sparing diuretic , 1969, Clinical pharmacology and therapeutics.

[16]  M. Glitzer,et al.  N-Amidino-3,5-diamino-6-chloropyrazine-carboxamide : an Active Diuretic in the Carboxamide Series , 1966, Nature.

[17]  T. Chalmers,et al.  Metabolic studies on the effects of sprinolacton. , 1963, Metabolism: clinical and experimental.

[18]  E. Ross.  Human assay of electrolyte-active steroids and their antagonists. , 1962, Clinical science.

[19]  G. M. Wilson,et al.  The action of hydroflumethiazide in relation to adrenal steroids and potassium loss. , 1960, Lancet.

[20]  B. B. Johnson.  Bioassay of adrenal cortical steroids on the basis of electrolyte excretion by rats: effects of 11-desoxy and 11-oxy-steroids. , 1954, Endocrinology.